Safinamide, (an alpha-aminoamide derivative, see the structure) is believed to have a novel dual mechanism of action based on the enhancement of the dopaminergic function and reduction of glutamatergic activity by inhibiting glutamate release. Encouraged by this fact safinamide, has been developed by Merck Serono. First Phase III trial results are really encouraging. Hope this research will go a long way to help an estimated 3 million people in the industrialized countries, who suffer from Parkinson’s disease.
The results indicate that safinamide, when used adjunctively to existing dopaminergic therapies for study patients in mid-to-late stages of Parkinson’s disease, increases daily “ON” time of motor functioning,” said Dr. Bernhard Kirschbaum, (Merck Serono’s Executive VP for Global Research and Development). I am sure these results will be, a further step towards providing the patients and doctors with urgently needed new treatment possibilities in the Neurodegenerative Diseases therapeutic area. More..